<DOC>
	<DOCNO>NCT00490009</DOCNO>
	<brief_summary>The purpose study obtain safety efficacy data use Bexxar patient relapsed/refractory diffuse large cell Non-Hodgkin 's lymphoma ( DLCL ) .</brief_summary>
	<brief_title>Phase 2 Study Bexxar Relapsed/Refractory DLCL</brief_title>
	<detailed_description>There lack efficacious treatment option patient relapsed/refractory diffuse large cell Non-Hodgkin 's lymphoma ( DLCL ) appropriate candidate stem cell transplantation . DLCL relatively radiosensitive disease patient DLCL report respond anti-CD20 monoclonal antibody ( MAB ) therapy . Therefore , radioimmunotherapy target CD20 rational promising therapeutic approach patient population . This study evaluate Bexxar safe efficacious diffuse large cell Non-Hodgkin 's lymphoma .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Diphenhydramine</mesh_term>
	<mesh_term>Promethazine</mesh_term>
	<mesh_term>Acetaminophen</mesh_term>
	<mesh_term>Iodine</mesh_term>
	<mesh_term>Lugol 's solution</mesh_term>
	<mesh_term>Iodine-131 anti-B1 antibody</mesh_term>
	<criteria>Histologicallyconfirmed , diffuse large cell lymphoma ( DLCL ) , CD20+ Bcell nonHodgkin lymphoma ( NHL ) relapse chemotherapy chemotherapy resistant , without prior history low grade NHL . The patient must fail least one chemotherapy regimen contain anthracycline equivalent chemotherapeutic agent . No anticancer treatment three week prior treatment dose Bexxar ( 6 week Rituximab , nitrosourea Mitomycin C ) Fully recover toxicity associate prior surgery , radiation , chemotherapy immunotherapy An Institutional Review Board ( IRB ) approve sign inform consent Age 19 year old Prestudy Karnofsky Performance Status ≥ 70 % Absolute neutrophil count ( ANC ) ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Hct &gt; 30 % Hgb &gt; 9.0 gm % Bilirubin ≤ 2.0 Creatinine ≤ 2.0 Bone marrow involvement lymphoma le 25 % ( bilateral bone marrow ) within 6 week enrollment Acceptable birth control method men woman Female patient pregnant Not lactate Prior myeloablative therapy bone marrow transplantation peripheral stem cell rescue Platelet count &lt; 100,000/mm³ Hypocellular bone marrow ( ≤ 15 % cellularity ) Marked reduction bone marrow precursor one cell line History fail stem cell collection Prior treatment Fludarabine Prior radioimmunotherapy Presence central nervous system ( CNS ) lymphoma Patients know HIV AIDSrelated lymphoma Patients evidence myelodysplasia bone marrow biopsy Patients receive prior external beam radiation therapy 25 % active bone marrow Patients receive filgrastim sargramostim therapy within 3 week prior treatment Pregnant Lactating Presence human antimouse antibody ( HAMA ) reactivity patient prior exposure murine antibody proteins Serious nonmalignant disease infection , , opinion investigator , would compromise protocol objective Another primary malignancy ( squamous cell basal cell carcinoma skin , situ carcinoma cervix , treated prostate cancer stable prostate specific antigen level ) patient diseasefree least 3 year Major surgery , diagnostic surgery , within 4 week Patients pleural effusion</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>